Silo Pharma, Inc.
SILO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | -0% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | -1,291.2% | 91.9% | 91.9% | -2,118.3% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $1 | $1 | $0 |
| SG&A Expenses | $0 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$2 |
| % Margin | -6,388.2% | -6,926.8% | -6,069.7% | -10,414.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$2 |
| % Margin | -6,160.5% | -6,681.2% | -5,721.9% | -9,600.7% |
| EPS | -0.12 | -0.19 | -0.23 | -0.39 |
| % Growth | 36.8% | 17.4% | 41% | – |
| EPS Diluted | -0.12 | -0.19 | -0.23 | -0.39 |
| Weighted Avg Shares Out | 9 | 6 | 4 | 4 |
| Weighted Avg Shares Out Dil | 9 | 6 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$2 |
| % Margin | -6,139.3% | -6,658.4% | -5,693.3% | -9,936.5% |